Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

May 15, 2021

Study Completion Date

May 15, 2021

Conditions
Healthy Volunteer Study
Interventions
DRUG

AT-527 550 mg + midazolam

"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"

DRUG

AT-527 550 mg + midazolam

"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"

Trial Locations (1)

Unknown

Atea Study Site, Montreal

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT04865445 - Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) | Biotech Hunter | Biotech Hunter